1-4 September 2022 , Madrid, Spain
![]() |
![]() |
![]() |
![]() |
P-01 | Deciphering the epigenetic dependencies of intrahepatic cholangiocarcinoma | Juan Lafuente-Barquero | ![]() |
![]() |
|||
P-03 | Metabolic characterization of non-alcoholic fatty liver disease-related hepatocellular carcinoma | Monika Lewinska | ![]() |
![]() |
|||
P-05 | Multidimensional analyses reveal immunosuppressive microenvironment of hepatitis B virus-related hepatocellular carcinoma | Yunhua Lee | ![]() |
![]() |
|||
P-06 | Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic-cholangiocarcinoma. | margherita rimini | ![]() |
![]() |
|||
P-08 | Identifying regulatory transcription factors in primary liver cancer cell lineage commitment using single cell ATAC sequencing | Amanda Craig | ![]() |
![]() |
|||
P-11 | A small hairpin of long noncoding RNA NIHCOLE promotes DNA double-strand break synapsis and ligation in hepatocellular carcinoma | Puri Fortes | ![]() |
![]() |
|||
P-12 | Association of RNA sequencingbased gene signatures and clinical outcomes of lenvatinib (len) pembrolizumab (pembro) in hepatocellular carcinoma (HCC): results from study 116/KEYNOTE-524 | Richard S. Finn | ![]() |
![]() |
|||
P-13 | Regulatory diversity of cancer stem cell marker expressions underscores intertumoral heterogeneity with therapeutic implication in hepatocellular carcinoma | Yu Man Tsui | ![]() |
![]() |
|||
P-14 | Distinct lymphoid cell populations in intrahepatic cholangiocarcinoma and hepatocellular carcinoma | Emily Kawaler | ![]() |
![]() |
|||
P-15 | Patient-derived organoids as new in vitro model for the study of hepatoblastoma | Laura Zanatto | ![]() |
![]() |
|||
P-16 | Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutated clusters | Margherita Rimini | ![]() |
![]() |
|||
P-19 | PLATELET C3G REGULATES HEPATOCARCINOMA PROGRESSION. | Cristina Baquero | ![]() |
![]() |
|||
P-20 | Utilizing MALDI imaging mass spectrometry to analyze N-glycosylation of patient-matched serum and tissue hepatocellular carcinoma | Andrew DelaCourt | ![]() |
![]() |
|||
P-21 | Dissecting the direct immunomodulatory potential of VEGF and PD-1 blockade in blood and tissue | Gloryanne Aidoo-Micah | ![]() |
![]() |
|||
P-22 | Kruppel-Like Factor 10 Deletion and Hepatocellular Carcinoma Development | Sung Hwan Yoo | ![]() |
![]() |
|||
P-23 | Evaluation of Stage Migration as a Predictor of Overall Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. A Multi-center Study | Neehar Parikh | ![]() |
![]() |
|||
P-24 | The tumor suppressor roles of miR-3185 in Hepatocellular Carcinoma | Inah Marie Aquino | ![]() |
![]() |
|||
P-25 | Dual role of TGF- signatures in human B viral multistep hepatocarcinogenesis: early and late responsive genes | Young Nyun Park | ![]() |
![]() |
|||
P-26 | IDH1 IN INTRAHEPATIC CHOLANGIOCARCINOMA: A COMPARATIVE GENOMIC ANALYSIS AND CLINICAL IMPACT. | margherita rimini | ![]() |
![]() |
|||
P-27 | Evaluating the roles of DNA-PK in hepatocellular carcinoma | Fanni Palinkas | ![]() |
![]() |
|||
P-28 | Preclinical proof-of-concept testing for potential synthetic lethality targeting homologous recombination-deficient hepatocellular carcinomas | Jihyun An | ![]() |
![]() |
|||
P-29 | The heterogeneity of Perivenous-type (CTNNB1-mutated) hepatocellular carcinomas involves inflammatory escape and STEM-cell features | Desquilles Lise | ![]() |
![]() |
|||
P-30 | Differential association of single nucleotide polymorphisms related to hepatocellular carcinoma in Hispanics and Caucasians | Andre Boonstra | ![]() |
![]() |
|||
P-31 | Analysis of distinct tumor associated macrophage (TAM) phenotypes and myeloid subsets in human intrahepatic cholangiocarcinoma (iCCA) compared to hepatocellular carcinoma (HCC) by single cell sequencing | Daniel Weissinger | ![]() |
![]() |
|||
P-32 | In vitro treatment of hepatocellular carcinoma organoids reveals additive rather than synergistic effects of doxorubicin and hypoxia | Lauriane Blukacz | ![]() |
![]() |
|||
P-33 | AURORA KINASE A IN HCC: A POSSIBLE ROLE IN PD-L1 REGULATION | Luca Grisetti | ![]() |
![]() |
|||
P-34 | HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis | Amit Singal | ![]() |
![]() |
|||
P-35 | Racial, Ethnic, and Socioeconomic Disparities in Treatment Delay among Patients with Hepatocellular Carcinoma in the United States | Amit Singal | ![]() |
![]() |
|||
P-36 | The importance of metabolic syndrome status for the risk of non-viral hepatocellular carcinoma: a nationwide study | Yuri Cho | ![]() |
![]() |
|||
P-37 | A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance | Ahlim Lee | ![]() |
![]() |
|||
P-38 | Healthcare costs and expenditures for Patients with Hepatocellular Carcinoma in the United States | Amit Singal | ![]() |
![]() |
|||
P-39 | Myosteatosis and visceral adiposity may be novel predictors for mortality in patients with hepatocellular carcinoma treated with sorafenib | Minkyu Kang | ![]() |
![]() |
|||
P-40 | Macrotrabecular-Massive histologic subtype is associated with ahigher riskof the recurrence of hepatoecelluar carcinoma | Sung Hwan Yoo | ![]() |
![]() |
|||
P-42 | Assessment of the compliance and influencing factors of liver cancer screening in a high-risk population: A cross-sectional study | Maomao Cao | ![]() |
![]() |
|||
P-44 | Predicting metabolic liver-specific fingerprint in Hepatocellular Carcinoma using a novel bioinformatics pipeline | Sergio Barace | ![]() |
![]() |
|||
P-45 | Viral Hepatitis Status is Not Associated with Increased Odds of Complications Compared to Non-Viral Hepatitis After Liver Resection for Hepatocellular Carcinoma: A National Surgical Quality Improvement Program Analysis | Luckshi Rajendran | ![]() |
![]() |
|||
P-47 | LI-RADS Category on MRI Predicts Recurrence of Intrahepatic Cholangiocarcinoma After Surgery: A Multicenter Study | Sunyoung Lee | ![]() |
![]() |
|||
P-48 | Prevalence and pattern of alcohol consumption in patients with hepatocellular carcinoma. | María Varela Calvo | ![]() |
![]() |
|||
P-49 | Compliance of the screening for hepatocellular carcinoma in patients with chronic hepatitis B or C | Won Sohn | ![]() |
![]() |
|||
P-52 | Does HCC surveillance improve survival rate? A retrospective comparative study between patients diagnosed within and outside surveillance over a 10 year period A single centre study | Swetha Palanichamy | ![]() |
![]() |
|||
P-53 | Characteristics and survival of patients with hepatocellular carcinoma in natural history in a western country. | Maria Sánchez | ![]() |
![]() |
|||
P-54 | Epidemiology, real-world treatment patterns and clinical outcomes of systemic treatments in unresectable hepatocellular carcinoma: a systematic review | Cal Shephard | ![]() |
![]() |
|||
P-58 | A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B | Hye Won Lee | ![]() |
![]() |
|||
P-59 | Urinary Microbiome-Based Metagenomic Signature for Non-invasive Diagnosis of Hepatocellular Carcinoma | Eun Ju Cho | ![]() |
![]() |
|||
P-61 | Estimating postsurgical outcomes of patients with a single hepatocellular carcinoma using gadoxetic acid-enhanced MRI: Risk scoring system development and validation | Bohyun Kim | ![]() |
![]() |
|||
P-63 | Protein biomarkers in HCC | Robin Zenlander | ![]() |
![]() |
|||
P-65 | Accurate diagnosis of HCC in cirrhotic patients with a novel protease assay compared to standard AFP | Tram Tran | ![]() |
![]() |
|||
P-67 | Noninvasive prediction of hepatocellular carcinoma development after oral antiviral therapy in patients with chronic hepatitis C: A multicenter study | Yu Rim Lee | ![]() |
![]() |
|||
P-68 | Differentiation hepatic angiomyolipoma and hepatocellular carcinoma in patients without risk of hepatocellular carcinoma | Hyungjin Rhee | ![]() |
![]() |
|||
P-69 | Early Detection of Hepatocellular Carcinoma via methylation-sensitive high-resolution melting-based Liquid Biopsy | Su Jong Yu | ![]() |
![]() |
|||
P-70 | Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy | Jae Seung Lee | ![]() |
![]() |
|||
P-72 | Hepatocellular carcinoma with fatty change: association of underlying liver disease and clinicopathologic characteristics | Jae Hyon Park | ![]() |
![]() |
|||
P-74 | FROM TISSUE TO SERUM- SPATIAL OMICS USED TO DEVELOP A NOVEL BIOMARKER FOR CHOLANGIOCARCINOMA | Shaaron Ochoa Rios | ![]() |
![]() |
|||
P-75 | Association between intensity of imaging surveillance and clinical outcomes in patients with hepatocellular carcinoma | Jeong Ah Hwang | ![]() |
![]() |
|||
P-77 | Low risk of seeding following percutaneous needle biopsy of intrahepatic cholangiocarcinoma (iCCA) | Gianluca Fornoni | ![]() |
![]() |
|||
P-78 | Optimal imaging criteria and modality to determine Milan criteria for prediction of post-transplant HCC recurrence after locoregional treatment | Mi-Suk Park | ![]() |
![]() |
|||
P-80 | Circulating cytokines reflective of the etiology-specific immune environment in cirrhosis and HCC | Andre Boonstra | ![]() |
![]() |
|||
P-81 | Albumin RNA in situ hybridization and filamin A are helpful for differentiation of small duct type intrahepatic cholangiocarcinoma from extrahepatic adenocarcinomas | Young Nyun Park | ![]() |
![]() |
|||
P-82 | Impact of the COVID-19 pandemic in the diagnosis and therapy of single hepatocellular carcinoma less than 3 cm in a western country. | Maria Valera | ![]() |
![]() |
|||
P-83 | Plasma cytokine levels and circulating DNA in plasma as biomarkers of response to immunotherapy in hepatocellular carcinoma | Elena Vargas-Accarino | ![]() |
![]() |
|||
P-86 | Diagnostic Performance of LI-RADS v2018 Versus KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using MRI: A Meta-Analysis of Comparative Studies | Sunyoung Lee | ![]() |
![]() |
|||
P-87 | Investigating historic aMAP scores in a population of NAFLD/NASH related Hepatocellular Carcinoma patients and studying variations in scores between cirrhotic and non-cirrhotic groups | Avisnata Das | ![]() |
![]() |
|||
P-89 | Screening with a reduction of liver cancer mortality: a systematic review and meta-analysis | Maomao Cao | ![]() |
![]() |
|||
P-93 | EURopean Field of Practice Study of Atezolizumab and Bevacizumab in HepatoCellular Carcinoma (EURAB-HCC) | Gloryanne Aidoo-Micah | ![]() |
![]() |
|||
P-94 | Treatment-related adverse events and improved survival in pts treated with atezolizumab plus bevacizumab: a global, real-world study. | Antonio DAlessio | ![]() |
![]() |
|||
P-97 | Previous variceal bleeding is associated with variceal bleeding under atezolizumab-Bevacizumab treatment | Manon Allaire | ![]() |
![]() |
|||
P-99 | Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Final analysis of the prospective, observational REFINE study | kirhan ozgurdal | ![]() |
![]() |
|||
P-100 | RAdiation SEgmentectomy for cuRative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): A prospective, single-centre, single-arm study | Alex Sher | ![]() |
![]() |
|||
P-101 | Trial in progress: Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients with Hepatocellular Carcinoma Beyond Milan Criteria | Gonzalo Sapisochin | ![]() |
![]() |
|||
P-102 | Early Nivolumab addition to Regorafenib in patients with hepatocellular carcinoma progressing under first line therapy (GOING trial). Interim analysis and safety profile | Marco Sanduzzi Zamparelli | ![]() |
![]() |
|||
P-103 | A network meta-analysis of non-surgical locoregional therapies in patients with early hepatocellular carcinoma | Jihyun An | ![]() |
![]() |
|||
P-105 | Semaglutide prevents the progression of hepatocellular carcinoma in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH | Michael Feigh | ![]() |
![]() |
|||
P-106 | REACH-2 and REACH: Exploratory efficacy and safety results in Chinese hepatocellular carcinoma (HCC) patients with extrahepatic spread (EHS) | Junjun Liu | ![]() |
![]() |
|||
P-108 | Impact of dose adjustment on clinical outcome of lenvatinib-treated patients with advanced hepatocellular carcinoma (HCC) | Stephen Lam Chan | ![]() |
![]() |
|||
P-109 | Marked Interdisciplinary Differences in Treatment Strategies Exist in the Management of Combined Hepatocellular-cholangiocarcinoma Patients: An International Multicenter Evaluation of Hospital-wide Treatment Strategies | Marco Claasen | ![]() |
![]() |
|||
P-111 | A five year experience of assessing patients for liver transplantation in HCC: acceptance rates and outcomes. | Rosemary Faulkes | ![]() |
![]() |
|||
P-113 | R1 VASCULAR OR PARENCHYMAL MARGINS: WHAT IMPACT AFTER RESECTION OF INTRAHEPATIC CHOLANGIOCARCINOMA? | Mabilia Andrea | ![]() |
![]() |
|||
P-114 | Early variation of serum AFP predicts outcomes under atezolizumab/bevacizumab for advanced hepatocellular carcinoma | Claudia Campani | ![]() |
![]() |
|||
P-115 | Spontaneously ruptured hepatocellular carcinoma on non-cirrhotic liver: treatment and prognosis. | Marta Romero-Gutiérrez | ![]() |
![]() |
|||
P-116 | The cumulative incidence of hepatocellular carcinoma according to care cascade in patients with anti-HCV positive | HYUN WOONG LEE | ![]() |
![]() |
|||
P-117 | Renal disfunction in patients treated with atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma | Hitomi Takada | ![]() |
![]() |
|||
P-121 | PRIMER-1: A randomised phase II trial of Perioperative pembrolizumab and lenvatinib in resectable Hepatocellular Carcinoma (HCC) | Tim Meyer | ![]() |
![]() |
|||
P-122 | Perioperative Therapy with Durvalumab Plus Tremelimumab for Patients with Resectable Hepatocellular Carcinoma - A Phase II Trial (NEOTOMA) | OKane Grainne | ![]() |
![]() |
|||
P-123 | Surveillance in Liver Cancer The SILVER study | Rohini Sharma | ![]() |
![]() |
|||
P-124 | Open label, randomised, phase 2 study to evaluate the safety and efficacy of sorafenib with or without MTL-CEBPA, an immune-modulatory saRNA upregulating C/EBP-a, as second line treatment in advanced hepatocellular carcinoma (OUTREACH 2) | Nagy Habib | ![]() |
![]() |
|||
P-125 | Multiple arterial-phase of gadoxetic acid-enhanced MRI improves diagnosis of hepatocellular Carcinoma: Multicenter propensity score-matched analysis | Sang Hyun Choi | ![]() |
![]() |
|||
P-126 | Clinical efficacy of stereotactic ablative body radiotherapy for oligometastatic hepatocellular carcinoma: a multi-institutional retrospective study (KROG 20-04) | Tae Hyung Kim | ![]() |
![]() |
|||
P-128 | CT Radiomic Features of Colorectal Cancer Liver Metastasis for Predicting Upcoming Disease Progression After Initial Systemic Chemotherapy | Joon-IL Choi | ![]() |
![]() |
|||
P-129 | TERT promoter mutations identified by ddPCR on FFPE samples: a surrogate marker of entry into liver carcinogenesis | Aurelie Beaufrere | ![]() |
![]() |
|||
P-135 | An assessment of ed microRNAs in patients with hepatitis B, hepatitis C and with hepatocellular carcinoma | Janusz Szemraj | ![]() |
![]() |
|||
P-136 | Interleukin-15 co-expression induces robust in vivo expansion and antitumor effect of Glypican-3-specific CAR T cells in a patient with liver cancer | Tannaz Armaghany | ![]() |
![]() |
|||
P-137 | Transcriptome profiling of the intermediate cell carcinoma of the primary liver cancer | Byungchan Jang | ![]() |
![]() |
|||
P-138 | Single-cell derived gene signatures identify responders to checkpoint inhibition in bulk transcriptome from advanced hepatocellular carcinoma | Sarah Cappuyns | ![]() |
![]() |
|||
P-139 | Fast Deep learning quantification of tumor infiltrating lymphocytes with minimal training dataset | Grousset Ruben | ![]() |
![]() |
|||
P-140 | MALDI imaging: a powerful tool to decipher intra-tumoral heterogeneity: combined hepato-cholangiocarcinomas as proof of concept | Elia Gigante | ![]() |
![]() |
|||
P-141 | An image-based machine learning pipeline for the prediction of liver resection complexity from preoperative CT scans | Omar Ali | ![]() |
![]() |
|||
P-142 | External Validation of the FSAC Model Using On-Therapy Response of Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B; a multicenter study | Jae Seung Lee | ![]() |
![]() |
1-4 September 2022 , Madrid, Spain
![]() |
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|